Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Clinical trial NCT05489276 · UNKNOWN

Trial details

NCT number: NCT05489276
Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Hematological Tumors

Start date: 2022-03-22
Primary completion: 2023-10-01
Enrollment: 180

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.